VAX 2.0 – Moderna Announces That Human Trials Of New Hybrid Flu And COVID Messenger RNA Vaccine Are Officially Underway For Rollout In Late 2023 by Geoffrey Grider for Now The End Begins
On Sunday, Moderna’s Chief Medical Officer Dr. Paul Burton announced the messenger RNA vaccine maker had officially kicked off phase 1 ‘human trials’ for its new two-in-one hybrid Flu-COVID jab.
Lol, so you thought that all this was going to just ‘go away’, right? That’s soooo funny, after having established that yes, the world will indeed line up to receive the government injection, the New World Order has the Willy Wonka Golden Ticket of end times shenanigans. Messenger RNA is here to stay, and it’s going to start popping up everywhere you look. Should you be afraid of the messenger? Absolutely, unless of course you like having your genes edited by messenger RNA.
“An evil man seeketh only rebellion: therefore a cruel messenger shall be sent against him.” Proverbs 17:11 (KJB)
Moderna has updated their logo to proudly feature the term ‘messenger therapeutics‘ front and center where everyone can read it, no more having to hide it. One of these old days, they will kick off human trials of a new messenger vaccine that will be injected into the back of your right hand, or injected into your forehead. When that happens, run.
Moderna Announces ‘Human Trials’ of New Hybrid Flu-Covid Vaccine Are Officially Underway
FROM THE GATEWAY PUNDIT: According to Burton, who spoke exclusively with 9News Australia, phase one clinical trials for the hybrid vaccine are currently underway and progressing on schedule, with the new treatment expected to be rolled out between late 2023 and early 2024.
“A phase one trial of a combination flu and Covid vaccine is currently underway. Moderna plans to have that vaccine ready by next year or by early 2024.”
Moderna’s CMO also announced that the company is currently working on a “triple-threat” vaccine that will be made available sometime in 2024 or 2025, following the rollout of the hybrid ‘Flu-Rona’ vaccine. The third-generation treatment will also target a lung infection called respiratory syncytial virus (RSV), which is a common, contagious virus that causes infections of the respiratory tract, according to the CDC.
Just like with Covid, RSV has an extremely low mortality rate for the vast majority of people. But, the sCiEnCe says we need another experimental vaccine – and you must take it. Initial “human trials” for this triple vaccine are also expected to begin by the end of this year.